Pr ecis: These findings suggest how AMPK activation by cyclin D1 may couple cell proliferation to energy homeostasis.
Pr ecis: This potentially seminal study provides a preclinical proof of concept for repurposing the FDA-approved drug mibefradil as a mechanism-based treatment for deadly glioblastomas.
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Monitoring Tumor Response to Antivascular Therapy Using Non-Contrast Intravoxel Incoherent Motion Diffusion-Weighted MRI Changzheng Shi, Dexiang Liu, Zeyu Xiao, Dong Zhang, Guanfu Liu, Guanshu Liu, Hanwei Chen, and Liangping Luo Pr ecis: These findings highlight advantages of a novel noninvasive imaging technique that can be used to predict efficacy of antivascular therapies, without the need for contrast media.
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Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer
Pr ecis: These results suggest the repositioning of beta-blocker drugs, which are used widely to control hypertension and cardiac arrhythmias, to improve the survival of pancreatic cancer patients. 
ABOUT THE COVER
Immunometabolism is emerging as a critical determinant of cancer pathophysiology. A balance between tumor promotion and elimination is dependent on the state of functional polarization of macrophage populations within the tumor microenvironment. Lactic acid generated by lactate dehydrogenase-A is a key metabolite that facilities the immunosuppressive tumor microenvironment. Deletion of lactate dehydrogenase-A in myeloid cells restores the immunocompetent tumor microenvironment by reversing macrophage phenotype and antitumor immunity. Immunofluorescence staining revealed an increased number of infiltrating inducible nitric oxide synthase-positive (red) and M1-skewed F4.80-positive (green) macrophages in K-Ras tumors after deletion of lactate dehydrogenase-A. For details, see article by Seth and colleagues on page 3632. 
